Compare · AGIO vs NVO
AGIO vs NVO
Side-by-side comparison of Agios Pharmaceuticals Inc. (AGIO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGIO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $217.28B, about 91.5x AGIO ($2.37B).
- Over the past year, AGIO is up 1.6% and NVO is down 27.0% - AGIO leads by 28.6 points.
- AGIO has been more active in the news (20 items in the past 4 weeks vs 5 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Agios Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $39.93-1.64%
- $49.08-0.41%
- Market cap
- $2.37B
- $217.28B
- 1M return
- +38.84%
- +11.62%
- 1Y return
- +1.64%
- -27.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2013
- News (4w)
- 20
- 5
- Recent ratings
- 25
- 25
Agios Pharmaceuticals Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AGIO
- Director Backstrom Jay T. was granted 1,447 shares (SEC Form 4)
- U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
- SEC Form SCHEDULE 13G filed by Agios Pharmaceuticals Inc.
- Chief Medical Officer Gheuens Sarah sold $150,503 worth of shares (4,007 units at $37.56) as part of a pre-agreed trading plan and converted options into 8,375 shares, increasing direct ownership by 5% to 84,645 units (SEC Form 4) to cover withholding tax
- Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
- Director Ballal Rahul D. converted options into 2,816 shares, increasing direct ownership by 23% to 15,230 units (SEC Form 4)
- Director Capello Jeffrey D converted options into 2,816 shares, increasing direct ownership by 35% to 10,865 units (SEC Form 4)
- Director Foster-Cheek Kaye I converted options into 2,816 shares, increasing direct ownership by 38% to 10,284 units (SEC Form 4)
- Director Fouse Jacqualyn A converted options into 2,816 shares, increasing direct ownership by 2% to 154,156 units (SEC Form 4)
- Director Ho Maykin converted options into 2,816 shares, increasing direct ownership by 17% to 19,848 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S